https://orcid.org/0000-0002-8545-1067
Figures
Abstract
Chronic low-grade inflammation is regarded to an important signature of atherosclerosis (AS). Macrophage (Mψ) and related polarization have been demonstrated to play a crucial role in the occurrence and development of AS inflammation. Butyrate, a bioactive molecule produced by the intestinal flora, has been increasingly demonstrated to exhibit a vital role for regulating the inflammation in chronic metabolic diseases. However, the effectiveness and multiple anti-inflammation mechanisms of butyrate on AS still need to be further understood. ApoE−/− mice fed with high-fat diet as AS model were administered with sodium butyrate (NaB) for 14 weeks of treatment. Our results showed that the atherosclerotic lesion in the AS group was dramatically reduced after NaB intervention. Moreover, deteriorated routine parameters of AS including body weights (BWs), low-density lipoprotein (LDL-C), triglyceride (TG), total cholesterol (TC) were significantly reversed by NaB administration. Abnormal elevated plasma and aorta pro-inflammatory indicators including interleukin (IL)-1β, IL-6, IL-17A, tumor necrosis factor (TNF)-α and lipopolysaccharide (LPS), as well as reduced anti-inflammatory IL-10 in plasma were respectively rectified after NaB administration. Consistently, accumulated Mψ and associated imbalance of polarization in the arota were attenuated with NaB treatment. Importantly, we demonstrated that the suppression of Mψ and associated polarization of NaB was dependent on binding G-protein coupled receptor (GPR) and inhibiting histone deacetylase HDAC3. Moreover, we found that intestinal butyrate-producing bacteria, anti-inflammatory bacteria and intestinal tight junction protein zonula occludens-1 (ZO)-1 may contribute to this effectiveness. Intriguingly, according to transcriptome sequencing of atherosclerotic aorta, 29 elevated and 24 reduced miRNAs were found after NaB treatment, especially miR-7a-5p, suggesting that non-coding RNA may possess a potential role in the protection of NaB against AS. Correlation analysis showed that there were close complicated interactions among gut microbiota, inflammation and differential miRNAs. Collectively, this study revealed that dietary NaB may ameliorate atherosclerotic inflammation by regulating Mψ polarization via GPR43/HDAC-miRNAs axis in ApoE−/− mice.
Citation: Ma H, Yang L, Liu Y, Yan R, Wang R, Zhang P, et al. (2023) Butyrate suppresses atherosclerotic inflammation by regulating macrophages and polarization via GPR43/HDAC-miRNAs axis in ApoE−/− mice. PLoS ONE 18(3): e0282685. https://doi.org/10.1371/journal.pone.0282685
Editor: Michael Bader, Max Delbruck Centrum fur Molekulare Medizin Berlin Buch, GERMANY
Received: September 28, 2022; Accepted: February 17, 2023; Published: March 8, 2023
Copyright: © 2023 Ma et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Datasets are available in the Supporting Information S1 Datasets. All sequencing raw files are available at the NCBI with accession numbers: PRJNA825185, PRJNA825670.
Funding: This work was supported by the National Natural Science Foundation of China (Grant No. 82160691), Ningxia Natural Science Foundation, China (Grant No. 2021AAC05010), The Key Research and Development Projects of Ningxia, China (Grant No. 2018BEG02006). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors declared no conflict of interest.
Introduction
Atherosclerosis (AS) represents a basis of cardiovascular diseases with the highest morbidity and mortality worldwide [1], of which the pathological features are mainly described as inflammation and lipid metabolism disturbance [2]. Vascular intimal macrophages (Mψs) are thought to be responsible for the maintenance of atherosclerotic inflammation in the development of AS [3].
Numerous studies have shown that Mψs and associated polarization play a vital role in the initiation and development of AS inflammation [4–6]. M1 Mψ is mainly involved in the promotion of inflammatory response. In contrast, M2 Mψ shows anti-inflammation effect and promotes tissue repair by producing anti-inflammatory factors such as interleukin (IL)-10. In the pathological conditions, accumulating Mψs along with subsequently polarization to M1, are responsible for aggravating AS inflammation [7]. Conversely, M2 Mψ are thought to secret anti-inflammatory IL-10 and collagen, contributing to the stability of AS plaques [8]. Thus, the regulation of Mψ and associated M1/M2 polarization may be a potential therapeutic strategy for AS.
Accumulating evidence suggests that gut dysbiosis is closely associated with exacerbation of AS progression [9, 10]. The formation and rupture of atherosclerotic plaque are related to the high levels of gut microbiota-derived lipopolysaccharide (LPS) and inflammatory cytokines in the circulation [11]. Short-chain fatty acids (SCFAs), mainly acetate, propionate and butyrate, are the main end-products of the bacterial fermentation of nondigestible dietary fibers within the lumen of the mammalian colon [12]. Compared to other SCFAs, emerging studies have demonstrated that butyrate presents an anti-inflammatory effect in chronic metabolic diseases [13, 14]. Butyrate and related butyrate-producing bacteria are inversely correlated with atherosclerotic lesion [15–17].
Butyrate exerts an anti-inflammatory effect mainly by both binding to G protein-coupled receptors (GPRs) and inhibiting histone deacetylases (HDACs) [12]. Butyrate-binding receptors, GPRs, which mainly include GPR41, GPR43, and GPR109a, can suppress the recruitment of inflammatory cells and the production of pro-inflammatory cytokines. As a major butyrate receptor, GPR43 highly expressed in Mψ may mediate anti-inflammatory response [16]. Studies from animal models have confirmed that sodium butyrate could suppress the activation of nuclear factor-κB (NF-κB) pathway via GPR43 and β-arrestin-2 to inhibit inflammation [15, 18, 19]. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that exert significant impacts on metabolism-related pathways [20]. The elevation of PPARγ by butyrate was involved in the inhibition of NF-κB pathway, resulting in the improvement of inflammation [21]. Butyrate also affects the rate of neointima formation by reducing the activation of Nod-like receptor pyrin domain 3 (NLRP3) inflammasome [22]. Transcription factor specificity protein 1 (Sp1) is often compounded with histone deacetylases (HDACs) to regulate acetylation of target genes. Notably, butyrate as an inhibitor of HDACs influence the formation of the Sp1/HDAC complex [23].
MicroRNAs (miRNAs) play an critical role in the regulation of the development of AS [24]. MiRNAs are well-known for regulating gene expression at the post-transcriptional level by pairing with target sequences in the 3′ untranslated region of mRNAs. The endogenously expressed miRNAs play important roles in many physiological and pathological processes [25]. MiR-205 was epigenetically regulated by HDAC2 through an Sp1-mediated pathway [25]. MiR-7a/b protected against cardiac remodeling and hypoxia-induced injury in H9c2 cardiomyoblasts involving Sp1 and PARP-1 [26]. The bulk of evidence has demonstrated the central role of epigenetic machinery in Mψ polarization [27].
In the present study, we examined the effects of orally administered butyrate on AS progression and associated mechanisms including Mψ polarization in inflammation, gut microbiota, and the role of miRNAs in HFD-induced atherosclerotic Apolipoprotein E deficiency (ApoE−/−) mice.
Materials and methods
Animal experiments
All animal protocols used in this study were approved by the Ethics Committee of Ningxia Medical University (No. 2020–527). Thirty male Jackson (C57BL/6J) mice aged 8 weeks and weighing 18–22 g were purchased from Ningxia Medical Laboratory Animal Center. Thirty male ApoE−/− mice (8-week-old) were obtained from Vital River Laboratory Animal Technology Co., Ltd., Beijing, China. All the mice were maintained under standard, specific, and pathogen-free conditions in individual cages in a temperature-controlled room (ambient temperature 22 ± 1°C, air humidity 40–70%) with a 12 h light/dark cycle in Ningxia Medical Laboratory Animal Center. A high-fat diet (HFD) with 0.5% cholesterol (No. TP28520) was purchased from TROPHIC Animal Feed High-tech Co., Ltd., Nantong, China. The exact product description of HFD and normal diet were supported in S1 Table. Sodium butyrate (NaB, purity>98, No. V900464) was obtained from Sigma (St Louis, MO, USA).
Experimental design
As shown in Fig 1A, after one week of adaption the mice were randomly assigned to 4 groups (n = 15/each group): control group (CON), CON treated with NaB group (CON+NaB), atherosclerosis group (AS) and AS treated with NaB group (AS+NaB). C57BL/6J mice in the CON or ApoE−/− mice in AS were respectively fed normal or HFD diet. Meanwhile, mice in CON and AS groups were administered normal saline, as well as mice in CON+NaB and AS+NaB groups were fed with NaB (200mg/kg, dissolved by normal saline) by gavage once daily. During the experiment, body weights (BWs) were monitored weekly and food intake was recorded every 2 days. After 14 weeks of feeding, stool samples were freshly obtained and immediately frozen at −80°C for the subsequent analysis. All mice were euthanized with 4% sodium pentobarbital and associated indications were investigated. Blood samples were rapidly collected by orbital bleeding and centrifuged at 4°C (1,200 × g for 15 min) to obtain plasma samples, which were stored at −80°C for further study.
(A) Schematic time diagram of the experimental design. (B) Body weights (BWs) of 4 groups. (C) Food intake. (D) Triglyceride (TG). (E) Total cholesterol (TC). (F) High-density lipoprotein (HDL-C). (G) Low-density lipoprotein (LDL-C). Data were expressed as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. ns, no significant difference. CON: control group; CON+NaB: sodium butyrate (NaB)-fed control group; AS: model group; AS+NaB: NaB-fed model group.
Histology and morphometry evaluations of atherosclerotic lesions
The pathological changes in AS were measured with en face oil red O staining, HE staining, and Masson’s trichrome staining. Images captured with Canon EOS 70D camera were analyzed using Image J 8.0 software (National Institutes of Health, United States). The lesion area index was calculated as the percentage of aortic lumen area covered by atherosclerotic lesions. The necrotic core was measured by Image-Pro plus software, and the ratio of the positive area to the total plaque area was calculated for statistical analysis as previously described [28]. Observers were blinded to the experimental groups.
Flow cytometry
Mψs, the significant aortic inflammatory cells, were isolated from aortic tissues. Briefly, 1 g of aortic tissues was minced and suspended in 5 ml of Hanks balanced salt solution (HBSS) containing 0.1% (w/v) collagenase type IV (Sigma, United States) for 20 min at 37°C. Next, the specimen was washed with RPMI1640 containing 2% of fetal bovine serum (FBS) and then filtered through a 200-mesh nylon membrane. After centrifugation at 70 × g for 3 min at 4°C, the supernatants were discarded, and the pellets were resuspended in 3 ml HBSS. After the erythrocyte lysis, samples were centrifuged for 5 min at 500 × g, 4°C, and then washed 2 times. The final concentration was adjusted to 1 × 107 cells/ml. To stain Mψs, 1 μl of PE-anti-F4/80 antibody, APC-anti-iNOS antibody, BP450-anti-CD206 antibody, and FITC-anti-TLR4 antibody (Biolegend, United States) were simultaneously added in 100 μl of cell suspension and incubated on the ice in the dark for 30 min. The prepared samples were measured and analyzed using the Beckman Cyto FLEX flow cytometer (Beckman Bioscience, United States).
Plasma LPS assay
The plasma LPS level in each group was examined using a Limulus amebocyte lysate kit (Xiamen Bioendo Technology Co., Ltd., Xiamen, China) according to the manufacturer’s instruction. Briefly, the plasma was diluted with endotoxin-free water (1:4). Then 50 μl of diluted plasma was put into each well in a 96-well plate. At the initial time point, 50 μl of the Limulus amebocyte lysate reagent was added to each well. The plate was incubated at 37°C for 30 min. Then, 100 μl of chromogenic substrate warmed to 37°C was added to each well, and the incubation was extended for an additional 6 min at 37°C. Finally, the reaction was stopped by adding 100 μl of 25% solution of glacial acetic acid. Optical density at 545 nm was measured with a microplate reader (Thermo Scientific, United States).
Inflammatory cytokines
Tumor necrosis factor (TNF)-α, interferon (IFN)-γ, IL-6, IL-1β, IL-17A, and IL-10 were respectively determined by RayBiotech (QAM-INT-1-1) chips (Quantibody® Mouse Interleukin Array) according to the manufacturer’s instructions.
Measurements of plasma lipid profiles
Plasma levels of triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C) were measured by an automatic biochemical analyzer (AU400 Olympus, Japan).
Quantitative real-time PCR
Transcriptional mRNA levels of genes were performed by quantitative real-time PCR (qRT-PCR). After RNA was isolated from the aorta tissue, cDNA was synthesized using M-ML V reverse transcriptase (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. qPCR (ABI VII7 PCR System, Applied Biosystems; Thermo Fisher Scientific, Inc.) was conducted in a 20 μl reaction volume (10 μl SYBR Green Master Mix, 0.8 μl PCR Forward Primer (10 μM), 0.8 μl PCR Reverse Primer (10 μM), 0.4 μl ROX, 2 μl cDNA, and 6 μl nuclease-free water) with the following protocol: initiation at 95°C for 5 min, followed by 40 cycles of 95°C (5 sec) and 60°C (34 sec). GAPDH was used as a reference. The assay was performed in three replicate wells, and three parallel experiments for each sample were conducted. The 2-ΔΔCt methods were used to calculate relative RNA expression levels. Primers sequences were presented in S2 Table.
Gut microbiota analysis
The mice in each group were transferred to fresh and sterilized cages after 14 weeks of treatment. The fresh feces of each group were individually collected and immediately frozen into liquid nitrogen, finally stored at −80°C until the DNA extraction. Cetyltrimethylammonium bromide (CTAB) method [29] was used to extract the genomic DNA of samples, and then the purity and concentration of the DNA were detected by agarose gel electrophoresis and Nanodrop one (Thermo Fisher, USA). Briefly, 16S rRNA genes were amplified by using V3-V4 regions bacterial primers (341F 5’- CCTAYGGGRBGCASCAG-3’ and 806R 5’- GG ACTACNNGGGTATCTAAT-3’). All PCR reactions were carried out with Phusion1 HighFidelity PCR Master Mix (New England Biolabs, USA). Sequencing libraries were generated using the Ion Plus Fragment Library Kit 48 rxns (Thermo Scientific, USA). The library quality was assessed on the Qubit@ 2.0 Fluorometer (Thermo Scientific, USA). The library was sequenced on an Illumina HiSeq 2500 platform (Illumina, USA) by Beijing Nuo He Zhi Yuan Technology Co., Ltd., China.
Transcriptome sequencing and analysis
Whole aorta transcriptome library preparation and deep sequencing were conducted by Biomarker Technologies Co, Ltd. The purity was determined using an ultra-microspectrophotometer (optical density 260 nm, NanoDrop; Thermo Fisher Scientific, Inc.), n = 3/group. DESeq R package was used to identify the significantly dysregulated miRNAs with cut-off criteria: P<0.05 and |log2 fold change|>1.
GO and KEGG pathway analysis
To better understand the biological functions and potential mechanisms of miRNAs in the effectiveness of NaB on AS, GO enrichment and KEGG pathway analyses were employed on these predicted target genes of differentially expressed miRNAs. Briefly, GO analyses (www.geneontology.org) consisted of three components: biological process (BP), cellular component (CC), and molecular function (MF). KEGG analyses were carried out to investigate the potential significant pathways (http://www.genome.jp/kegg/).
Statistical analysis
The data shown as the mean ± SEM were conducted with Prism 8.01 (GraphPad Software Inc., CA, United States). Two-way analysis of variance (ANOVA) followed by the Turkey multiple-comparison test was used to determine statistical difference between experimental groups. Correlation analysis was performed using the Spearman method. P<0.05 was considered statistically significant.
Results
NaB alleviated physiological parameters and serum lipids
To assess whether the difference in diet intake contributes to the effects of NaB treatment, food consumption and body weights were monitored. The body weights in AS group showed a steady weight gain and subsequently increased after 14 weeks, compared to the CON group (Fig 1B). NaB treatment showed no effect on weight gain compared to AS group. In terms of food intake, the average intake of mice in each group was decreased during the intervention period, but without a significant difference (Fig 1C), suggesting that NaB administration showed no influence in energy intake.
After 14 weeks of treatment, the serum biochemical parameters of mice were respectively determined. Compared to the CON group, plasma levels of TG (P<0.05; Fig 1D), TC (P<0.001; Fig 1E), and LDL-C (P<0.001; Fig 1G) in AS group were notably increased. After NaB administration, plasma TC, TG and LDL-C levels were significantly rectified (Fig 1D, 1E and 1G). A decrease trend of HDL-C (Fig 1F) in plasma was observed in AS group without significant difference compared with CON group. It also showed no significant difference in HDL-C level in supplementary NaB group during HFD. Moreover, there was no significant difference in serum lipids between CON and CON+NaB groups. Collectively, these data demonstrated that NaB could protect against dyslipidemia in atherosclerotic ApoE−/− mice.
NaB consumption ameliorated atherosclerosis
To further elucidate the involvement of NaB in the amelioration of atherosclerosis, both en face analyses of the aorta and the cross-sectional analyses of the aortic sinus area were evaluated. Histopathologic staining including en face oil red O staining, oil red O staining, Masson’s trichrome staining and HE staining were used to measure atherosclerotic plaque, fibrosis, and pathological damage in the aortic root of the heart, respectively. As shown in Fig 2A, lesion area and necrotic core size in the aortic sinus were remarkably exacerbated in AS mice. The percentage of en face oil red O staining in the AS group was notably higher than that in the CON group (P<0.001; Fig 2B). Similar aggregated results of oil red O staining (P<0.01) and Masson’s trichrome staining (P<0.001) were separately observed in AS model, compared to the CON group (Fig 2C and 2D). In addition, H&E staining of the aortic sinus revealed a significant increase in necrotic core size in the AS group (Fig 2E). After intervention with NaB, the necrotic core size was decreased significantly. Intriguingly, these pathological lesions in AS were attenuated with NaB administration (P<0.05; Fig 2E). In addition, no lesion was found between the CON group and CON+NaB group (Fig 2B, 2C and 2D). Taken together, these results demonstrated that NaB intervention could ameliorate the atherosclerotic lesions.
(A) Representative sections of the valve area of the aortic root of the heart were stained with en face oil red O staining, oil red O staining, Masson’s trichrome staining and hematoxylin&eosin staining, respectively, Quantitative analysis as lesion area/total area (%). (B) face oil red O staining. (C) oil red O staining. (D) Masson’s trichrome staining and (E) Relative necrotic core area expressed as percentage of the total plaque area. *P<0.05, **P<0.01, ***P<0.001. ns, no significant difference. The bar of 500 μm was presented in the right corner of (A).
Dietary NaB significantly reduced chronic inflammation in AS
Mounting scientific proofs over decades have suggested that atherosclerosis represents a chronic inflammatory disorder [30]. Accumulating evidences support that NaB possesses the ability to reduce the expressions of pro-inflammatory cytokines [31]. We further examined concentrations of pro-inflammatory cytokines including IL-1β, IL-6, IL-17A, TNF-α, IFN-γ, as well as anti-inflammatory IL-10 (Fig 3A), respectively. The results showed that plasma levels of pro-inflammatory IL-1β, IL-6, IL-17A and IFN-γ in the AS group were significantly increased compared to the CON group, but the anti-inflammatory IL-10 was notably decreased. After the dietary NaB intervention, the concentrations of IL-1β, IL-6, IL-17A and IFN-γ in plasma were decreased and anti-inflammatory IL-10 was increased compared with those in the AS group.
(A) Plasma of mice from 4 groups were respectively collected for the determination of interleukin (IL)-1β, IL-6, IL-17A, IL-10, tumor necrosis factor (TNF)-α, interferon (IFN)-γ by RayBiotech chip detection. (B) RT-PCR was used to determine relative mRNA levels of IL-1β, IL-6, IL-17A, IL-10, TNF-a, and IFN-γ in aorta tissues. (C) Plasma lipopolysaccharide (LPS) levels in diverse groups were measured using a Limulus amebocyte lysate kit. *P<0.05, **P<0.01, ***P<0.001. ns, no significant difference.
In parallel, mRNA levels of in situ aortic inflammatory TNF-α, IL-1β, IL-6 IL-17A, IFN-γ, and IL-10 were determined to evaluate the effects of dietary NaB on plaque inflammation in atherosclerotic mice (Fig 3B). Similar to the above plasma levels of inflammation, aggravated TNF-α, IL-1β, IL-6, IFN-γ (all P<0.05) in aortic tissues were remarkably decreased after dietary NaB intervention. Moreover, a decrease trend of anti-inflammatory IL-10 in aorta was observed in AS group without significant difference compared to CON group, which also showed no significant difference after NaB treatment. These results suggested that dietary NaB treatment ameliorated the inflammation in atherosclerotic ApoE−/− mice.
Dietary NaB reduced plasma LPS levels
LPS-mediated inflammation based on gut-heart axis has been thought to contribute to the AS aggravation (29). Thus, we further tested the plasma LPS in AS. Plasma LPS levels in AS group were higher than those in the CON group (P<0.001; Fig 3C), which was significantly decreased after NaB intervention (P<0.05; Fig 3C), demonstrating that dietary NaB may ameliorate LPS-induced intestinal barrier dysfunction and subsequent translocated circulating endotoxemia.
NaB regulated atherosclerotic Mψs and M1/M2 polarization in mice
Mψs and associated polarization play a vital role in the formation and progression of atherosclerotic lesions [32]. To further analyze the effects of NaB on aortic Mψs, aortic F4/80+TLR4+ Mψs were measured by flow cytometry (Fig 4A). The ratios of aortic F4/80+ cells and F4/80+TLR4+ cells were increased in AS group compared to CON group (P<0.01; Fig 4B and 4C). However, the proportions of F4/80+ TLR4+ cells and F4/80+ cells were respectively lower after NaB treatment (P<0.05; Fig 4B and 4C). As shown in Fig 4D, iNOS, M1 Mψs-associated marker, in aortic plaques of model group was increased significantly (P<0.05; Fig 4E) compared with control group, and exhibited an obvious decrease with NaB treatment. Conversely, the expression of M2 Mψs marker CD206 in aorta of model group after dietary NaB intervention was elevated (Fig 4F and 4G), suggesting that NaB may alleviate AS via regulating total Mψs and polarization by suppressing M1 polarization and enhancing M2 activation.
(A) Flow cytometry analysis of aorta F4/80+TLR4+ Mψs in diverse groups. (B) The proportion of aorta F4/80+ Mψs. (C) The proportion of aorta F4/80+ TLR4+ Mψs. (D) Flow cytometry analysis of aorta F4/80+ iNOS+ M1 Mψs in diverse groups. (E) The proportion of aorta F4/80+ iNOS+ M1 Mψs. (F) Flow cytometry analysis of aorta F4/80+ CD206+ M2 Mψs in diverse groups. (G) The proportion of aorta F4/80+ CD206+ M2 Mψs. *P<0.05, **P<0.01, ***P<0.001. ns, no significant difference. All experiments were performed in triplicate. Mψ: macrophage; TLR4: Toll-like receptor 4.
NaB inhibited inflammation via GPR43 and HDAC mediated pathways
NaB exerts pleiotropic biological effects mainly by activating G protein-coupled receptors (GPRs) and inhibiting histone deacetylases (HDACs) [33]. As shown in Fig 5, compared with HFD-fed mice, NaB treatment elevated the transcriptional levels of GPR43, PPAR-γ, and β-arrestin-2, as well as down-regulated HDAC3, Sp1, NF-κB, and NLRP3. These results indicated that GPR43 and HDAC signaling pathway may probably involve in NaB-mediated regulation of inflammation in the atherosclerotic ApoE−/− mice.
RT-PCR was used to determine relative mRNA levels of HDAC1 (A); HDAC2 (B); HADC3 (C); Sp1 (D); PPAR-γ (E); GPR43 (F); β-arrestin-2 G); NF-κB (H) and NLRP3 (I) in aorta tissues. *P<0.05, **P<0.01, ***P<0.001. ns, no significant difference.
NaB consumption enriched intestinal butyrate-producing and anti-inflammatory bacteria
Growing evidence has demonstrated that gut dysbiosis is closely associated with the development of AS [29, 34–37]. To further confirm the effects of NaB on gut microbiota in diverse groups, bacterial community were investigated by 16S rRNA sequencing and analysis.
At the phylum level, microbial composition of all mice was dominated with Firmicutes (CON 44%, CON+NaB 45%, AS 73%, AS+NaB 43%) and Bacteroidetes (CON 35%, CON+NaB 42%, AS 0.05%, AS+NaB 15%) (Fig 6A). We found an obviously decreased abundance of Firmicutes (P< 0.001) and an increase trend of Bacteroidetes (P = 0.06) in AS+NaB group compared to the AS group (Fig 6C and 6D). The ratio of Firmicutes/Bacteroidetes (F/B) was increased (P<0.05; Fig 6E) in the AS group, which was reversely decreased after the intervention of dietary NaB (P<0.05; Fig 6E). Thus, the NaB had a major influence on the F/B ratio under the HFD feeding in the atherosclerotic mice. In addition, NaB also restored the increased abundance of Verrucomicrobiota in AS (P<0.01; Fig 6F).
(A-I) The phylum and the genus levels. (J) The mRNA expression level of ZO-1 in different groups. *P<0.05, **P<0.01, ***P<0.001. ns, no significant difference.
The relative abundance of microbiota at the genus level was shown in Fig 6B. The relative abundance of Akkermansia and Faecalibaculum in the AS+NaB group were significantly increased compared to the AS group (all P<0.01, Fig 6G and 6I). Additionally, Bifidobacterium in the CON+ NaB group was higher than those in the CON group (P<0.01; Fig 6H). In brief, the data summarized here clearly indicated that exogenous butyrate altered the composition of the microbiota in AS. Importantly, butyrate-producing bacteria Faecalibaculum was increased in the AS+ NaB group compared to the AS group (Fig 6I). The above-mentioned results indicated that butyrate reduced atherosclerosis development by regulating butyrate-producing bacteria of gut microbiota.
To further assess the integrity of gut mucosal barrier after the above rectification of gut dysbiosis with NaB treatment, tight junction protein ZO-1 expression in diverse groups was determined (Fig 6J). Compared to the CON group, intestinal ZO-1 expression in AS group was significantly reduced, indicating that the integrity of gut mucosa was impaired in AS. However, gut mucosal ZO-1 level of AS mice showed a notable elevation after the supplementation with NaB, demonstrating that NaB administration may contribute to enhancing the integrity of the gut barrier (P<0.001; Fig 6J).
Correlation analysis among gut microbiota, inflammation and serum lipids
For the assessment of interactions among the differential bacteria microbiota, inflammatory indicators, serum lipids in AS, correlation analysis was performed in AS and AS treated with NaB (Fig 7). In brief, the abundance of Firmicutes was found to be positively associated with the levels of pro-inflammatory indicators (TNF-α, IL-1β, IL-6, IL-17A, IFN-γ, LPS) and serum lipids (TG, TC, LDL-C), but negatively correlated with IL-10 and HDL-C. However, the beneficial bacteria Bacteroidetes were negatively correlated with metabolic and pro-inflammatory indicators (TG, TC, LDL-C, LPS, IL-1β, IL-17A, TNF-α, IFN-γ). The abundance of butyrate-producing bacteria Faecalibaculum exhibited a positive correlation with IL-10, whereas negatively correlated with TC and LDL-C. Taken together, there were close and complicated interactions among gut bacteria, inflammation, and serum lipids in AS and AS treated with NaB.
The heat map showing the correlation of different microbial abundance with inflammatory indicators and serum lipids. The intensity of the color indicates the degree of correlation between the corresponding factor and each microbial species, which is obtained by Spearman’s correlation analysis. *P<0.05, **P<0.01, ***P<0.001.
NaB consumption notably modulated the aorta miRNAs
MicroRNAs (miRNAs) play an essential role in the regulation of atherosclerosis [24]. The cDNA and sRNA libraries of aortic tissue samples were sequenced. Moreover, counts of clean reads and mapped ratio of sequencing data were shown in Table 1. Under the NaB treatment, 53 miRNAs were identified to express differentially with the significance (P<0.05; Table 2). Compared with the AS group, up-regulated 29 miRNAs and down-regulated 24 miRNAs in the AS+NaB group were shown in the cluster heatmap (Fig 8A) and volcano diagram (Fig 8B). The most significantly enriched KEGG pathways were shown in Fig 8C. For the miRNAs, endocytosis was the most significantly enriched pathway. GO analysis contained the biological process (BP), cellular component (CC), and molecular function (MF) for host linear transcripts. Based on the GO enrichment analysis of the trans targeted genes of miRNA, the most significantly enriched BP, CC, and MF were signal transduction, nucleus, and ATP binding (Fig 8D–8F), respectively. It was indicated that atherosclerotic miRNAs were different with or without NaB treatment, suggesting that NaB may play an important role in atherosclerosis-related GO terms such as transcription factor activity. As shown in Fig 8G, compared with the AS group, a total of 25 inflammation-associated miRNAs were found. MiR-7a-5p was up-regulated after the supplementation with NaB in comparison with the AS group (P<0.05; Table 2). Increasing evidence supports that miR-7a-5p plays an important role in regulating the inflammatory process in inflammatory diseases [38]. MiR-7a-5p was identified as a protector of cardiac remodeling and hypoxia-induced injury in H9c2 cardiomyoblasts [26]. Subsequently, qRT-PCR of miR-7a-5p was identified in consistent with the RNA-sequencing results (P<0.01; Fig 8H). Moreover, we found that miR-7a-5p was negatively correlated with metabolic and pro-inflammatory indicators (TG, TC, LDL-C, TNF-α, IL-1β, IL-6, IL-17A, IFN-γ, LPS) and positively associated with HDL-C and IL-10 (Fig 8I). Taken together, the attenuation of dietary NaB on AS may be probably dependent on miRNAs regulation.
(A) MiRNAs cluster heatmap with differential expression in AS and AS+NaB groups. (B) Differential-expression volcano diagram. (C) KEGG enrichment plot of differential miRNA host genes between AS and AS+NaB. (D-F) GO analysis of miRNA host genes between AS and AS+NaB. (G) Inflammation-related miRNAs. (H) The expression level of miR7a-5p was measured by real-time PCR. (I) Correlation analyses between the relative abundance of miR7a-5p and other related indicators. *P<0.05, **P<0.01, ***P<0.001. ns, no significant difference.
Discussion
In the present study, we investigated the efficacy of dietary NaB intervention on chronic AS. At the end of this experiment, we demonstrated that NaB could ameliorate the AS, as well as further revealed that the effectiveness was mainly attributed to the suppression of atherosclerotic inflammation by regulating Mψs polarization via GPR43/ HDAC-miRNAs axis in ApoE−/− mice.
ApoE-/- mice fed with HFD, a classical mouse model of AS, were used to test the hypothesis that NaB protect against AS. Since ApoE-/- mice have a C57BL/6J genetic background, C57BL/6J mice were used as a CON group. Moreover, in parallel with previous studies, our results demonstrated that long-term NaB administration could ameliorate AS in mice [39, 40].
Dyslipidemias including hypercholesterolemia and hyperlipidemia, can further enhance the risk for atherosclerotic CVDs [41]. NaB has been thought to show a beneficial effect on the lipid metabolism in diverse chronic diseases [1]. Consistently, in this study, decreases of TG, LDL-C, TC levels, but an increase of HDL-C in AS with dietary NaB treatment demonstrated that NaB could attenuate lipid disturbance in AS development.
Mψs exerts a predominant inflammatory role in AS lesion formation as well as plaque rupture [42]. In the present study, the proportions of F4/80+ cells and F4/80+ TLR4+ cells were all significantly decreased with the dietary NaB administration, suggesting that the anti-inflammation effect of NaB was ascribed to the inhibition of inflammatory Mψs. Decreased levels of M1 iNOS, and elevated M2 CD206 indicated that NaB possessed the ability to ameliorate inflammation of AS via regulating Mψ M1/M2 polarization.
Concomitant with the reduction of pro-inflammatory Mψs, NaB administration also decreased the levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17A, IFN-γ), but elevated anti-inflammatory IL-10. A similar study found that combination of pro-inflammatory cytokines led to chronic inflammatory response in the arterial wall, which is thought to promote disease progression characterized by atherosclerotic plaque buildup [43]. Furthermore, the dramatic changes in Mψ described above may be responsible for the release of pro-inflammatory cytokines by LPS-TLR4-NF-κB/Nod 3-like receptor protein (NLRP3) inflammasome signaling [44]. However, whether other immune cells such as regulatory T cells (Tregs), Th17 cells and myeloid suppressor cells (MDSCs) are involved in the anti-inflammatory effects of the NaB treatment on AS still needs to be further explored.
After translocation into arteries, LPS links gut microbiota and pathogen-induced systemic inflammation, subsequently binds to TLR4 of Mψs, leading to an inflammatory cascade that ultimately aggravates AS [11]. Endotoxemia causes the activation of M1 Mψs, which promote the formation of AS foam cells [45]. Elevated plasma LPS level in AS indicated impaired gut barrier with abnormal integrity and permeability in consistent with previous reports [37, 46]. Importantly, this elevated plasma LPS of AS group was conversely changed by NaB intervention, suggesting that the effectiveness of NaB on chronic inflammation in AS was partially due to the reduction of LPS translocation.
Among the numerous pathogenesis in AS, gut dysbiosis is increasingly thought to be critical in the inflammation of AS [47]. We found that NaB could notably change gut microbial composition by improving anti-inflammatory related bacteria (Bacteroidetes, Verrucomicrobiota, Akkermansia, Bifidobacterium) and butyrate-producing bacteria (Faecalibaculum), but decreasing Firmicutes and F/B ratio, suggesting that the protection of NaB against the inflammation of AS may partially attribute to the rectification of gut dysbiosis. Akkermansia and Bifidobacterium are conductive to the reduction of LPS leakage via protecting the gut mucosal barrier function [48, 49]. Bifidobacterium plays a synergistic effect in the improvement of inflammation to further alleviated the atherosclerosis [50]. Akkermansia is implicated in declining aortic lesions and atherosclerosis [51]. Akkermansia can also stimulate goblet cells to secret mucus and elevate the expression of gut junction proteins [52]. In addition to these microbiota, butyrate-producing bacteria Faecalibaculum is also lack in atherosclerotic CVD [53].
Positive correlations of increased Firmicutes with metabolic indicators (TG, TC, LDL-C) demonstrated that these pathogenic bacteria were related to the lipid dysmetabolism of AS. In contrast, Bacteroidetes were negatively correlated with these indicators. These findings indicated that gut microbiota may play crucial role in etiology of dyslipidemia. However, the underlying mechanisms of gut microbiota affects blood lipid levels remains unclear. It has been addressed that gut bacteria could generate SCFAs, modulating hepatic and/or systemic lipid and glucose metabolism via the activation of nuclear or GPCRs [54, 55]. Meanwhile, gut microbiota also modulate the metabolism of bile acids which is the main end-product of cholesterol [56].
Gut microbiota is closely associated with the integrity and permeability of gut barrier which is indicated by the tight junction proteins [53, 57]. In our study, the improvement of tight junction protein ZO-1 revealed that oral NaB intervention may contribute to the attenuation of the integrity of gut barrier, thereby reducing LPS translocation and ultimately suppressing atherosclerotic chronic inflammation.
Apart from the above restorement of NaB on gut dysbosis-related inflammation, NaB also directly serve as a novel anti-inflammation approach by binding to the GPR43 [16, 58]. Thus, we speculated and proved that NaB regulated inflammatory Mψs and their polarization through GPR43-β-arrestin-2-mediated pathways by increasing the levels of M2 (CD206, IL-10 and PPARγ) and reducing M1 indicators (iNOS, TNF-α and NF-κB/NLRP3).
As an inhibitor of HDACs, NaB can regulate the inflammation through the acetylation regulation of inflammatory gene expression [59]. In the present study, LPS significantly increased the accumulation of HDAC1-3/Sp1 and reduced PPARγ acetylation in Mψs. However, dietary NaB restored PPARγ acetylation and expression, PPARγ further repressed pro-inflammatory NF-κB /NLRP3 pathways. In parallel with our study, Saemann et al. has demonstrated that butyrate could inhibit the secretion of TNF-α and the activation of NF-κB and up-regulate the expression of anti-inflammatory factors IL-10 in LPS-activated mononuclear cells and neutrophils via HDAC inhibition [60]. Moreover, butyrate also increases the expression of PPARγ, which act as an E3 ubiquitin ligase of NF-κB/p65 to promote its degradation [61]. Here, we demonstrated that NaB may prevent atherosclerotic chronic inflammation through the HDAC/Sp1/PPARγ/NF-κB or NLRP3 signaling pathway, but the exact mechanism still needs to be further investigated in vitro experiment.
MiRNAs have emerged as evolutionarily conserved, noncoding small RNAs that serve as important regulators and fine-tuners of a range of pathophysiological cellular effects and molecular signaling pathways involved in atherosclerosis [62]. In recent years, there has been increased interesting in the role of miRNAs on macrophage polarization which mainly rely on the regulation of vital signaling pathways [63, 64]. Inhibition of miRNA-155 attenuates AS via reducing M1 Mψ polarization and inflammatory responses in mice [64]. MiRNA-130a suppression can protect against atherosclerosis through inhibiting inflammation by regulating the PPARγ/NF-κB expression [65]. In addition, miRNAs are closely related to HDACs in different human chronic diseases and cancerogenic pathways [66]. To date, many miRNAs have been found directly targeted by HDACs in chronic metabolic diseases [67–69]. Intriguingly, in our study, 25 differential inflammation-related miRNAs candidates were found by transcriptomic analysis after long-term dietary NaB supplementation. Especially, miR-7a-5p was identified and proved to be closely interacted with the inflammation. Due to the complex relationships about roles of above differential miRNAs in AS with NaB treatment, the underlying mechanisms need to be further investigated.
Conclusion
Our study provides a new evidence that butyrate could ameliorate the progression of inflammation in atherosclerosis through regulating macrophage polarization via GPR43-related and HDAC/PPAR-γ/NF-κB/NLRP3/miRNAs signal pathways. Schematic mechanism is shown in Fig 9.
Supporting information
S1 Table. Ingredients of high fat diet and normal diet.
https://doi.org/10.1371/journal.pone.0282685.s002
(DOC)
S2 Table. Primer sequences of above genes and miRNAs.
https://doi.org/10.1371/journal.pone.0282685.s003
(XLSX)
Acknowledgments
The authors gratefully acknowledge all team members for their contributions to this article.
References
- 1. Du Y, Li X, Su C, Xi M, Zhang X, Jiang Z, et al. Butyrate protects against high-fat diet-induced atherosclerosis via up-regulating ABCA1 expression in apolipoprotein E-deficiency mice. Brit J Pharmacol. 2020;177(8):1754–72. pmid:31769014
- 2. Troseid M, Andersen GO, Broch K, Hov JR. The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions. Ebiomedicine. 2020;52:102649. pmid:32062353
- 3. Cai Y, Wen J, Ma S, Mai Z, Zhan Q, Wang Y, et al. Huang-Lian-Jie-Du Decoction Attenuates Atherosclerosis and Increases Plaque Stability in High-Fat Diet-Induced ApoE() Mice by Inhibiting M1 Macrophage Polarization and Promoting M2 Macrophage Polarization. Front Physiol. 2021;12:666449. pmid:34539422
- 4. Leipner J, Dederichs TS, von Ehr A, Rauterberg S, Ehlert C, Merz J, et al. Myeloid cell-specific Irf5 deficiency stabilizes atherosclerotic plaques in Apoe() mice. Mol Metab. 2021;53:101250. pmid:33991749
- 5. Kiepura A, Stachyra K, Wisniewska A, Kus K, Czepiel K, Suski M, et al. The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE-Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype. Int J Mol Sci. 2021;22(18). pmid:34575934
- 6. Zhou J, Liu L, Wu P, Zhao L, Wu Y. Fusobacterium nucleatum Accelerates Atherosclerosis via Macrophage-Driven Aberrant Proinflammatory Response and Lipid Metabolism. Front Microbiol. 2022;13:798685. pmid:35359716
- 7. Wang C, Ma C, Gong L, Guo Y, Fu K, Zhang Y, et al. Macrophage Polarization and Its Role in Liver Disease. Front Immunol. 2021;12:803037. pmid:34970275
- 8. Park SH. Regulation of Macrophage Activation and Differentiation in Atherosclerosis. J Lipid Atheroscler. 2021;10(3):251–67. pmid:34621697
- 9. Sanchez-Rodriguez E, Egea-Zorrilla A, Plaza-Diaz J, Aragon-Vela J, Munoz-Quezada S, Tercedor-Sanchez L, et al. The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases. Nutrients. 2020;12(3). pmid:32110880
- 10. Troseid M, Andersen GO, Broch K, Hov JR. The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions. Ebiomedicine. 2020;52:102649. pmid:32062353
- 11. Zhu L, Zhang D, Zhu H, Zhu J, Weng S, Dong L, et al. Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe() mice. Atherosclerosis. 2018;268:117–26. pmid:29202334
- 12. He J, Zhang P, Shen L, Niu L, Tan Y, Chen L, et al. Short-Chain Fatty Acids and Their Association with Signalling Pathways in Inflammation, Glucose and Lipid Metabolism. Int J Mol Sci. 2020;21(17). pmid:32887215
- 13. Li Z, Yi CX, Katiraei S, Kooijman S, Zhou E, Chung CK, et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. Gut. 2018;67(7):1269–79. pmid:29101261
- 14. Hayden RE, Kussaibati R, Cronin LM, Pratt G, Roberts C, Drayson MT, et al. Bezafibrate and medroxyprogesterone acetate target resting and CD40L-stimulated primary marginal zone lymphoma and show promise in indolent B-cell non-Hodgkin lymphomas. Leukemia Lymphoma. 2015;56(4):1079–87. pmid:24996440
- 15. Pirozzi C, Francisco V, Guida FD, Gomez R, Lago F, Pino J, et al. Butyrate Modulates Inflammation in Chondrocytes via GPR43 Receptor. Cell Physiol Biochem. 2018;51(1):228–43. pmid:30448827
- 16. Li M, van Esch B, Wagenaar G, Garssen J, Folkerts G, Henricks P. Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells. Eur J Pharmacol. 2018;831:52–9. pmid:29750914
- 17. Meli R, Mattace RG, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol. 2014;5:177. pmid:24795720
- 18. Luo QJ, Sun MX, Guo YW, Tan SW, Wu XY, Abassa KK, et al. Sodium butyrate protects against lipopolysaccharide-induced liver injury partially via the GPR43/ beta-arrestin-2/NF-kappaB network. Gastroenterol Rep. 2021;9(2):154–65. pmid:34026223
- 19. Sun X, Luo S, Jiang C, Tang Y, Cao Z, Jia H, et al. Sodium butyrate reduces bovine mammary epithelial cell inflammatory responses induced by exogenous lipopolysaccharide, by inactivating NF-kappaB signaling. J Dairy Sci. 2020;103(9):8388–97. pmid:32622605
- 20. Oh H, Visvalingam V, Wahli W. The PPAR-microbiota-metabolic organ trilogy to fine-tune physiology. Faseb J. 2019;33(9):9706–30. pmid:31237779
- 21. Aguilar EC, Da SJ, Navia-Pelaez JM, Leonel AJ, Lopes LG, Menezes-Garcia Z, et al. Sodium butyrate modulates adipocyte expansion, adipogenesis, and insulin receptor signaling by upregulation of PPAR-gamma in obese Apo E knockout mice. Nutrition. 2018;47:75–82. pmid:29429540
- 22. Yuan X, Wang L, Bhat OM, Lohner H, Li PL. Differential effects of short chain fatty acids on endothelial Nlrp3 inflammasome activation and neointima formation: Antioxidant action of butyrate. Redox Biol. 2018;16:21–31. pmid:29475132
- 23. Huang W, Zhou J, Zhang G, Zhang Y, Wang H. Decreased H3K9 acetylation level of LXRalpha mediated dexamethasone-induced placental cholesterol transport dysfunction. Bba-Mol Cell Biol L. 2019;1864(12):158524. pmid:31513924
- 24. Schober A, Maleki SS, Nazari-Jahantigh M. Regulatory Non-coding RNAs in Atherosclerosis. Handb Exp Pharmacol. 2022;270:463–92. pmid:33454857
- 25. Zheng Z, Zhang S, Chen J, Zou M, Yang Y, Lu W, et al. The HDAC2/SP1/miR-205 feedback loop contributes to tubular epithelial cell extracellular matrix production in diabetic kidney disease. Clin Sci. 2022;136(3):223–38. pmid:35084460
- 26. Li R, Geng HH, Xiao J, Qin XT, Wang F, Xing JH, et al. miR-7a/b attenuates post-myocardial infarction remodeling and protects H9c2 cardiomyoblast against hypoxia-induced apoptosis involving Sp1 and PARP-1. Sci Rep-Uk. 2016;6:29082. pmid:27384152
- 27. Yang H, Sun Y, Li Q, Jin F, Dai Y. Diverse Epigenetic Regulations of Macrophages in Atherosclerosis. Front Cardiovasc Med. 2022;9:868788. pmid:35425818
- 28. She ZG, Zheng W, Wei YS, Chen HZ, Wang AB, Li HL, et al. Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice. Circ Res. 2009;104(10):1160–8. pmid:19359600
- 29. Li Y, Yu Z, Liu Y, Wang T, Liu Y, Bai Z, et al. Dietary alpha-Linolenic Acid-Rich Flaxseed Oil Ameliorates High-Fat Diet-Induced Atherosclerosis via Gut Microbiota-Inflammation-Artery Axis in ApoE () Mice. Front Cardiovasc Med. 2022;9:830781. pmid:35295260
- 30. Mehu M, Narasimhulu CA, Singla DK. Inflammatory Cells in Atherosclerosis. Antioxidants-Basel. 2022;11(2). pmid:35204116
- 31. Bayazid AB, Kim JG, Azam S, Jeong SA, Kim DH, Park CW, et al. Sodium butyrate ameliorates neurotoxicity and exerts anti-inflammatory effects in high fat diet-fed mice. Food Chem Toxicol. 2022;159:112743. pmid:34890760
- 32. Koelwyn GJ, Corr EM, Erbay E, Moore KJ. Regulation of macrophage immunometabolism in atherosclerosis. Nat Immunol. 2018;19(6):526–37. pmid:29777212
- 33. Xiao Y, Guo Z, Li Z, Ling H, Song C. Role and mechanism of action of butyrate in atherosclerotic diseases: a review. J Appl Microbiol. 2021;131(2):543–52. pmid:33098194
- 34. Cao RY, Zhang Y, Feng Z, Liu S, Liu Y, Zheng H, et al. The Effective Role of Natural Product Berberine in Modulating Oxidative Stress and Inflammation Related Atherosclerosis: Novel Insights Into the Gut-Heart Axis Evidenced by Genetic Sequencing Analysis. Front Pharmacol. 2021;12:764994. pmid:35002703
- 35. Yoo JY, Sniffen S, McGill PK, Pallaval VB, Chidipi B. Gut Dysbiosis and Immune System in Atherosclerotic Cardiovascular Disease (ACVD). Microorganisms. 2022;10(1). pmid:35056557
- 36. Haghikia A, Zimmermann F, Schumann P, Jasina A, Roessler J, Schmidt D, et al. Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. Eur Heart J. 2022;43(6):518–33. pmid:34597388
- 37. Yan N, Wang L, Li Y, Wang T, Yang L, Yan R, et al. Metformin intervention ameliorates AS in ApoE-/- mice through restoring gut dysbiosis and anti-inflammation. Plos One. 2021;16(7):e254321. pmid:34264978
- 38. Yin B, Tian-Chu H, Ling-Fen X. Protection by microRNA-7a-5p Antagomir Against Intestinal Mucosal Injury Related to the JNK Pathway in TNBS-Induced Experimental Colitis. Turk J Gastroenterol. 2021;32(5):431–6. pmid:34231472
- 39. Chen Y, Xu C, Huang R, Song J, Li D, Xia M. Butyrate from pectin fermentation inhibits intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E-deficient mice. J Nutr Biochem. 2018;56:175–82. pmid:29574331
- 40. Aguilar EC, Leonel AJ, Teixeira LG, Silva AR, Silva JF, Pelaez JM, et al. Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFkappaB activation. Nutr Metab Cardiovas. 2014;24(6):606–13. pmid:24602606
- 41. Thobani A, Hassen L, Mehta LS, Agarwala A. Management of Hypercholesterolemia in Pregnant Women with Atherosclerotic Cardiovascular Disease. Curr Atheroscler Rep. 2021;23(10):58. pmid:34345940
- 42. Doddapattar P, Dhanesha N, Chorawala MR, Tinsman C, Jain M, Nayak MK, et al. Endothelial Cell-Derived Von Willebrand Factor, But Not Platelet-Derived, Promotes Atherosclerosis in Apolipoprotein E-Deficient Mice. Arterioscl Throm Vas. 2018;38(3):520–8. pmid:29348121
- 43. Yang B, Qin Q, Xu L, Lv X, Liu Z, Song E, et al. Polychlorinated Biphenyl Quinone Promotes Atherosclerosis through Lipid Accumulation and Endoplasmic Reticulum Stress via CD36. Chem Res Toxicol. 2020;33(6):1497–507. pmid:32434321
- 44. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54(1):24–38. pmid:18160725
- 45. Blaut M. Gut microbiota and energy balance: role in obesity. P Nutr Soc. 2015;74(3):227–34. pmid:25518735
- 46. Bao T, He F, Zhang X, Zhu L, Wang Z, Lu H, et al. Inulin Exerts Beneficial Effects on Non-Alcoholic Fatty Liver Disease via Modulating gut Microbiome and Suppressing the Lipopolysaccharide-Toll-Like Receptor 4-Mpsi-Nuclear Factor-kappaB-Nod-Like Receptor Protein 3 Pathway via gut-Liver Axis in Mice. Front Pharmacol. 2020;11:558525. pmid:33390939
- 47. Liang X, Zhang Z, Lv Y, Tong L, Liu T, Yi H, et al. Reduction of intestinal trimethylamine by probiotics ameliorated lipid metabolic disorders associated with atherosclerosis. Nutrition. 2020;79–80:110941. pmid:32858376
- 48. Zhang T, Ji X, Lu G, Zhang F. The potential of Akkermansia muciniphila in inflammatory bowel disease. Appl Microbiol Biot. 2021;105(14–15):5785–94. pmid:34312713
- 49. Ling X, Linglong P, Weixia D, Hong W. Protective Effects of Bifidobacterium on Intestinal Barrier Function in LPS-Induced Enterocyte Barrier Injury of Caco-2 Monolayers and in a Rat NEC Model. Plos One. 2016;11(8):e161635. pmid:27551722
- 50. Liang X, Zhang Z, Lv Y, Lu H, Liu T, Yi H, et al. Krill Oil Combined with Bifidobacterium animalis subsp. lactis F1-7 Alleviates the Atherosclerosis of ApoE() Mice. Foods. 2021;10(10). pmid:34681423
- 51. Hasani A, Ebrahimzadeh S, Hemmati F, Khabbaz A, Hasani A, Gholizadeh P. The role of Akkermansia muciniphila in obesity, diabetes and atherosclerosis. J Med Microbiol. 2021;70(10). pmid:34623232
- 52. Grander C, Adolph TE, Wieser V, Lowe P, Wrzosek L, Gyongyosi B, et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut. 2018;67(5):891–901. pmid:28550049
- 53. Yan N, Wang L, Li Y, Wang T, Yang L, Yan R, et al. Metformin intervention ameliorates AS in ApoE-/- mice through restoring gut dysbiosis and anti-inflammation. Plos One. 2021;16(7):e254321. pmid:34264978
- 54. Liu Y, Song X, Zhou H, Zhou X, Xia Y, Dong X, et al. Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo. Front Microbiol. 2018;9:530. pmid:29623075
- 55. Zhou C, Gao X, Cao X, Tian G, Huang C, Guo L, et al. Gut Microbiota and Serum Metabolite Potential Interactions in Growing Layer Hens Exposed to High-Ambient Temperature. Front Nutr. 2022;9:877975. pmid:35571932
- 56. Zhu Y, Zhang JY, Wei YL, Hao JY, Lei YQ, Zhao WB, et al. The polyphenol-rich extract from chokeberry (Aronia melanocarpa L.) modulates gut microbiota and improves lipid metabolism in diet-induced obese rats. Nutr Metab. 2020;17:54. pmid:32655675
- 57. Sugita K, Kabashima K. Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel diseases. J Leukocyte Biol. 2020;107(5):749–62. pmid:32108379
- 58. Zhao J, Hu J, Ma X. Sodium caprylate improves intestinal mucosal barrier function and antioxidant capacity by altering gut microbial metabolism. Food Funct. 2021;12(20):9750–62. pmid:34664601
- 59. Huuskonen J, Suuronen T, Nuutinen T, Kyrylenko S, Salminen A. Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. Brit J Pharmacol. 2004;141(5):874–80. pmid:14744800
- 60. Saemann MD, Bohmig GA, Osterreicher CH, Burtscher H, Parolini O, Diakos C, et al. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. Faseb J. 2000;14(15):2380–2. pmid:11024006
- 61. Hou Y, Moreau F, Chadee K. PPARgamma is an E3 ligase that induces the degradation of NFkappaB/p65. Nat Commun. 2012;3:1300. pmid:23250430
- 62. Feinberg MW, Moore KJ. MicroRNA Regulation of Atherosclerosis. Circ Res. 2016;118(4):703–20. pmid:26892968
- 63. Dai Y, Wang S, Chang S, Ren D, Shali S, Li C, et al. M2 macrophage-derived exosomes carry microRNA-148a to alleviate myocardial ischemia/reperfusion injury via inhibiting TXNIP and the TLR4/NF-kappaB/NLRP3 inflammasome signaling pathway. J Mol Cell Cardiol. 2020;142:65–79. pmid:32087217
- 64. Hu J, Huang CX, Rao PP, Zhou JP, Wang X, Tang L, et al. Inhibition of microRNA-155 attenuates sympathetic neural remodeling following myocardial infarction via reducing M1 macrophage polarization and inflammatory responses in mice. Eur J Pharmacol. 2019;851:122–32. pmid:30721702
- 65. Liu F, Liu Y, Du Y, Li Y. MiRNA-130a promotes inflammation to accelerate atherosclerosis via the regulation of proliferator-activated receptor gamma (PPARgamma) expression. Anatol J Cardiol. 2021;25(9):630–7. pmid:34498594
- 66. Klieser E, Urbas R, Swierczynski S, Stattner S, Primavesi F, Jager T, et al. HDAC-Linked "Proliferative" miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors. Int J Mol Sci. 2018;19(9). pmid:30223590
- 67. Cadavid IC, Da FG, Margis R. HDAC inhibitor affects soybean miRNA482bd expression under salt and osmotic stress. J Plant Physiol. 2020;253:153261. pmid:32947244
- 68. Conte M, Dell’Aversana C, Sgueglia G, Carissimo A, Altucci L. HDAC2-dependent miRNA signature in acute myeloid leukemia. Febs Lett. 2019;593(18):2574–84. pmid:31254352
- 69. Li Y, Zhang K, Mao W. Inhibition of miR34a prevents endothelial cell apoptosis by directly targeting HDAC1 in the setting of atherosclerosis. Mol Med Rep. 2018;17(3):4645–50. pmid:29328474